Terry Anderson v. Novartis Pharmaceuticals Corp

443 F. App'x 58
CourtCourt of Appeals for the Sixth Circuit
DecidedAugust 23, 2011
Docket09-6147, 09-6272, 09-6274
StatusUnpublished
Cited by15 cases

This text of 443 F. App'x 58 (Terry Anderson v. Novartis Pharmaceuticals Corp) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Terry Anderson v. Novartis Pharmaceuticals Corp, 443 F. App'x 58 (6th Cir. 2011).

Opinion

BOYCE F. MARTIN, JR., Circuit Judge.

Punnose Thomas, Edwin Melau, and Terry Anderson appeal the decisions of the district court granting summary judgment in favor of Novartis Pharmaceuticals Corporation and prohibiting their treating physicians from offering expert testimony on the cause of their injuries. We AFFIRM.

I.

These cases arise out of a series of lawsuits filed by individuals who developed osteonecrosis of the jaw, a severe bone disease affecting the jaw, allegedly as a result of taking Zometa and Aredia. Zometa and Aredia are prescription bis- *60 phosphonate 1 drugs produced by Novartis that are given intravenously, most often to patients with cancerous conditions. The drugs are effective at preventing pathological fractures, spinal cord compression, and other bone pains. Although the Food and Drug Administration approved both drugs, many individuals claim to have developed osteonecrosis of the jaw as a result of receiving this medication. Osteonecrosis of the jaw results in the gums being eaten away until the bone is exposed.

Thomas, Melau, and Anderson each filed a separate lawsuit against Novartis alleging that they developed osteonecrosis of the jaw as a result of the Zometa infusions they received. The Judicial Panel on Mul-tidistrict Litigation transferred these cases to the Middle District of Tennessee for consolidated proceedings.

To establish general causation, whether Zometa can cause osteonecrosis of the jaw, the plaintiffs retained experts. To establish specific causation, whether Zometa caused each individual plaintiffs osteone-crosis of the jaw, the plaintiffs planned to offer non-retained expert testimony from their treating physicians. However, the district court granted Novartis’s motions to exclude the expert testimony of these treating physicians. And, because there was no evidence to establish specific causation, granted Novartis’s motions for summary judgment.

II.

We review a district court’s decision to exclude expert testimony for abuse of discretion. Tamraz v. Lincoln Elec. Co., 620 F.3d 665, 668 (6th Cir.2010). “A district court abuses its discretion if it bases its ruling on an erroneous view of the law or a clearly erroneous assessment of the evidence.” Ky. Speedway, LLC v. Nat’l Assoc. of Stock Car Auto Racing, Inc., 588 F.3d 908, 915 (6th Cir.2009).

Under Daubert and its progeny, district courts must exercise a gatekeeping role in screening the reliability of expert testimony to keep “junk science” away from juries. Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). Consistent with this directive, Federal Rule of Evidence 702 provides that:

If scientific, technical, or other specialized knowledge will assist the trier of fact to ... determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training, or education, may testify thereto in the form of an opinion or otherwise, if (1) the testimony is based upon sufficient facts or data, (2) the testimony is the product of reliable principles and methods, and (3) the witness has applied the principles and methods reliably to the facts of the case.

This rule gives district courts broad discretion to determine whether a putative expert’s testimony would be inadmissible junk science or instead would be testimony falling within the “range where experts might reasonably differ.” Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 153, 119 S.Ct. 1167, 143 L.Ed.2d 238 (1999); Gen. Elec. Co. v. Joiner, 522 U.S. 136, 146, 118 S.Ct. 512, 139 L.Ed.2d 508 (1997). “Thus, we will not substitute our own judgment for that of the district court and will reverse an evidentiary decision only where we are left with a definite and firm conviction that [the district court] committed a clear error of judgment.” In re Scrap Metal Antitrust Litig., 527 F.3d 517, 528 (6th Cir.2008) (internal quotation marks and citation omitted); see also Nolan v. *61 Memphis City Sch., 589 F.3d 257, 265 (6th Cir.2009) (holding that “[b]road discretion is given to district courts in determinations of admissibility ... and those decisions will not be lightly overturned”).

Generally a treating physician can provide expert testimony regarding a patient’s illness, the appropriate diagnosis, and the cause of the illness even if the physician is not among the world’s foremost authorities on the matters. See Gass v. Marriott Hotel Servs., Inc., 558 F.3d 419, 426 (6th Cir.2009); Fielden v. CSX Transp., Inc., 482 F.3d 866, 870 (6th Cir.2007). However, a treating physician’s testimony is still subject to the requirements in Daubert. Before permitting a physician to testify, the district court must be persuaded that (1) the reasoning or methodology underlying his or her testimony is scientifically valid; and (2) he or she has properly applied that reasoning or methodology to the facts at issue to aid the trier of fact. See Gass, 558 F.3d at 426; In re Scrap Metal Antitrust Litig., 527 F.3d at 529-30 (“The task for the district court in deciding whether an expert’s opinion is reliable is not to determine whether it is correct, but rather to determine whether it rests upon a reliable foundation, as opposed to, say, unsupported speculation.”).

In each of these cases the district court held that the treating physicians could not give expert opinion testimony on the issue of specific causation. In reaching these conclusions, the district court relied in part on the physicians’ statements that they did not consider themselves to be experts about osteonecrosis of the jaw. While a witness’s self-assessment may be relevant, ultimately the district court — and not the individuals testifying — must determine whether the proposed testimony is sufficiently reliable and relevant to be admitted. We have previously explained that “[t]he ‘ipse dixit of the expert’ is alone not sufficient to permit the admission of an opinion.” Tamraz, 620 F.3d at 671. In this situation, the Daubert

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bledsoe v. FCA US LLC
E.D. Michigan, 2022
Thomas v. Bauman
E.D. Michigan, 2022
Avendt v. Covidien Inc.
262 F. Supp. 3d 493 (E.D. Michigan, 2017)
Jones v. Novartis Pharmaceuticals Corp.
235 F. Supp. 3d 1244 (N.D. Alabama, 2017)
Harvey v. Novartis Pharmaceutical Corp.
895 F. Supp. 2d 1206 (N.D. Alabama, 2012)
Clarissa Simmons v. Novartis Pharmaceuticals Corp.
483 F. App'x 182 (Sixth Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
443 F. App'x 58, Counsel Stack Legal Research, https://law.counselstack.com/opinion/terry-anderson-v-novartis-pharmaceuticals-corp-ca6-2011.